MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation ; volume:15 ; number:1 ; day:6 ; month:2 ; year:2015 ; pages:1-8 ; date:12.2015
BMC cancer ; 15, Heft 1 (6.2.2015), 1-8, 12.2015
- Urheber
-
Noro, Rintaro
Seike, Masahiro
Zou, Fenfei
Soeno, Chie
Matsuda, Kuniko
Sugano, Teppei
Nishijima, Nobuhiko
Matsumoto, Masaru
Kitamura, Kazuhiro
Kosaihira, Seiji
Minegishi, Yuji
Yoshimura, Akinobu
Kubota, Kaoru
Gemma, Akihiko
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-015-1019-1
- URN
-
urn:nbn:de:101:1-2021081719412334707229
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Noro, Rintaro
- Seike, Masahiro
- Zou, Fenfei
- Soeno, Chie
- Matsuda, Kuniko
- Sugano, Teppei
- Nishijima, Nobuhiko
- Matsumoto, Masaru
- Kitamura, Kazuhiro
- Kosaihira, Seiji
- Minegishi, Yuji
- Yoshimura, Akinobu
- Kubota, Kaoru
- Gemma, Akihiko
- SpringerLink (Online service)
Ähnliche Objekte (12)
Progression-free or overall survival…revisited in BOLERO-2
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
Association between intermediate end points, progression-free survival, and overall survival in first-line advanced or recurrent endometrial cancer
Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival
Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy
Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
Interstitial brachytherapy for hepatocellular carcinoma : Analysis of prognostic factors for overall survival and progression-free survival and application of a risk stratification model
Interstitial Brachytherapy for Hepatocellular Carcinoma: Analysis of Prognostic Factors for Overall Survival and Progression-Free Survival and Application of a Risk Stratification Model
Cholangitis and Interruptions of Neoadjuvant Chemotherapy Associate with Reduced Overall and Progression-Free Survival in Pancreatic Cancer
Progression-free or overall survival…revisited in BOLERO-2
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
Association between intermediate end points, progression-free survival, and overall survival in first-line advanced or recurrent endometrial cancer
Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival
Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy
Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
Interstitial brachytherapy for hepatocellular carcinoma : Analysis of prognostic factors for overall survival and progression-free survival and application of a risk stratification model
Interstitial Brachytherapy for Hepatocellular Carcinoma: Analysis of Prognostic Factors for Overall Survival and Progression-Free Survival and Application of a Risk Stratification Model
Cholangitis and Interruptions of Neoadjuvant Chemotherapy Associate with Reduced Overall and Progression-Free Survival in Pancreatic Cancer
Progression-free or overall survival…revisited in BOLERO-2
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
Association between intermediate end points, progression-free survival, and overall survival in first-line advanced or recurrent endometrial cancer
Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival
Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy
Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
Interstitial brachytherapy for hepatocellular carcinoma : Analysis of prognostic factors for overall survival and progression-free survival and application of a risk stratification model
Interstitial Brachytherapy for Hepatocellular Carcinoma: Analysis of Prognostic Factors for Overall Survival and Progression-Free Survival and Application of a Risk Stratification Model